Carotuximab Completed Phase 2 Trials for Primary Peritoneal Carcinoma / Recurrent Ovarian Cancer / Fallopian Tube Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01381861Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma